Docoh
Loading...

XOMA XOMA

XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA's pioneering efforts in the discovery and development of antibody therapeutics. The Company's royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.

Company profile

Ticker
XOMA, XOMAP, XOMAO
Exchange
Website
CEO
James Neal
Employees
Incorporated
Location
Fiscal year end
Former names
XOMA CORP /DE/, XOMA LTD /DE/
SEC CIK
IRS number
942756657

XOMA stock data

(
)

Calendar

6 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from XOMA earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 69.95M 69.95M 69.95M 69.95M 69.95M 69.95M
Cash burn (monthly) 5.47M (positive/no burn) 2.46M (positive/no burn) 304.67K (positive/no burn)
Cash used (since last report) 22.35M n/a 10.04M n/a 1.24M n/a
Cash remaining 47.6M n/a 59.91M n/a 68.71M n/a
Runway (months of cash) 8.7 n/a 24.4 n/a 225.5 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Jun 21 Neal James R Common Shares Sell Dispose S No No 35.1333 686 24.1K 11,821.6
25 Jun 21 Neal James R Common Shares Sell Dispose S No No 34.304 1,171 40.17K 12,507.6
25 Jun 21 Neal James R Common Shares Sell Dispose S No No 33.3597 7,170.4 239.2K 13,678.6
19 May 21 Limber Joseph M Non-Qualified Share Option Common Shares Grant Aquire A No No 31.04 5,101 158.34K 5,101
19 May 21 Wyszomierski Jack L Non-Qualified Share Option Common Shares Grant Aquire A No No 31.04 5,101 158.34K 5,101
19 May 21 Kosacz Barbara Non-Qualified Share Option Common Shares Grant Aquire A No No 31.04 5,101 158.34K 5,101
19 May 21 Van Ness W Denman Non-Qualified Share Option Common Shares Grant Aquire A No No 31.04 5,101 158.34K 5,101

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

87.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 60 60
Opened positions 9 13 -30.8%
Closed positions 9 7 +28.6%
Increased positions 12 18 -33.3%
Reduced positions 23 11 +109.1%
13F shares
Current Prev Q Change
Total value 455.38M 487.99M -6.7%
Total shares 9.9M 10.62M -6.8%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Biotechnology Value Fund L P 3.53M $144.08M -15.6%
BVF 3.53M $144.08M -15.6%
FMR 651.7K $26.6M NEW
BLK Blackrock 478.99K $19.55M +0.4%
Opaleye Management 437.5K $17.85M -3.8%
Vanguard 389.03K $15.88M -6.4%
Stonepine Capital Management 163.27K $6.66M +31.5%
Geode Capital Management 133.85K $5.46M -8.8%
STT State Street 105.95K $4.32M +2.3%
NTRS Northern Trust 98.86K $4.03M -14.5%
Largest transactions
Shares Bought/sold Change
FMR 651.7K +651.7K NEW
Biotechnology Value Fund L P 3.53M -651.7K -15.6%
BVF 3.53M -651.7K -15.6%
Stonepine Capital Management 163.27K +39.14K +31.5%
IVZ Invesco 0 -33.6K EXIT
Vanguard 389.03K -26.46K -6.4%
Opaleye Management 437.5K -17.5K -3.8%
NTRS Northern Trust 98.86K -16.82K -14.5%
Millennium Management 15.39K +15.39K NEW
JPM JPMorgan Chase & Co. 17.32K +14.62K +543.0%

Financial report summary

?
Risks
  • Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s) or licensee(s) under the applicable license agreement(s) covering such potential royalties and/or milestones, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.
  • Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.
  • We have significantly restructured our business and revised our business plan and there are no assurances that we will be able to successfully implement our revised business plan or successfully operate as a royalty aggregator.
  • We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies, if available, to resolve any disputes resulting from any such audit.
  • The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.
  • Our royalty aggregator strategy may require that we register with the SEC as an “investment company” in accordance with the Investment Company Act of 1940.
  • Our licensees or royalty-agreement counterparties or their licensees could be subject to natural disasters, public health crises, political crises and other catastrophic events that could hinder or disrupt development efforts.
  • Because many of the companies with which we do business also are in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.
  • We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.
  • We use leverage in connection with our capital deployment, which magnifies the potential for loss if the potential royalties acquired or generated through out-licensing and royalty purchase agreements do not generate sufficient income to us.*
  • We and our partners rely heavily on license and collaboration relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including our ability to receive milestone payments and future potential royalty and other revenues. License or collaboration agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our potential milestones, royalties and other payments.
  • Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our potential milestone and royalty providers’ product candidate development.
  • Agreements with other third parties, many of which are significant to our business, expose us to numerous risks.
  • Failure of our potential milestone and royalty providers’ product candidates to meet current Good Manufacturing Practices standards may subject our licensees to delays in regulatory approval and penalties for noncompliance.
  • Certain of our technologies are in-licensed from third parties, so our and our licensees’ capabilities use of them may be restricted and subject to additional risks.
  • We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions.
  • If our potential royalty providers’ therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.
  • Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates.
  • New products and technologies of other companies may render some or all of our potential milestone and royalty providers’ product candidates noncompetitive or obsolete.
  • Our potential royalty providers may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of our products, which would prevent our potential royalty providers’ products from becoming profitable and negatively affect the royalties we may receive.
  • We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.
  • We are exposed to an increased risk of product liability claims.
  • If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers’ ability to compete in the market will be harmed, and we may not realize our profit potential.
  • Litigation regarding intellectual property and/or the enforcement of our contractual rights against licensees and third parties can be costly and expose us to risks of counterclaims against us.
  • The loss or COVID-19 related absence of any of our personnel, including our Chief Executive Officer or Chief Financial Officer, could delay or prevent achieving our objectives.
  • Because we are a small biopharmaceutical focused company with limited resources, we may not be able to attract and retain qualified personnel.
  • Natural disasters, power shortages, power interruptions or other calamities at our Emeryville headquarters could disrupt our business and adversely affect our operations.
  • Our business and operations would suffer in the event of system failures.
  • Data breaches and cyberattacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.
  • Significant disruptions of information technology systems, including cloud-based systems, or breaches of data security could adversely affect our business.
  • Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be removed voluntarily from the market.
  • Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.
  • We and our potential milestone and royalty providers are subject to various state and federal healthcare-related laws and regulations that may impact the commercialization of our product candidates for which we possess milestone or royalty rights or could subject us to significant fines and penalties.
  • As we or our potential milestone and royalty providers do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.
  • Our share price may be volatile, and there may not be an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock.*
  • Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.
  • We have issued equity securities, and may issue additional equity securities from time to time, that materially and adversely affect the price of our common stock, including our Series X preferred stock, Series A Preferred Stock and depositary shares representing interests in our Series B Preferred Stock.*
  • We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.*
  • Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.
  • As a public company in the United States, we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our internal controls over financial reporting are effective.
  • Our ability to use our net operating loss carry-forwards and other tax attributes will be substantially limited by Section 382 of the U.S. Internal Revenue Code.
  • The 2017 tax reform law, as modified by 2020 tax legislation, and possible future changes in tax laws or regulations could adversely affect our business and financial condition.
  • Stockholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management’s time and attention from our business, and have a material adverse effect on our results of operations.
Management Discussion
  • Revenue from contracts with customers includes upfront fees, milestone payments and royalties related to the out-licensing of our product candidates and technologies. The decrease for the three months ended March 31, 2021, as compared to the same period in 2020, was primarily due to $0.5 million in revenue recognized in the first quarter of 2020 related to a milestone event under our license agreement with Compugen.
  • The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Due to the impact of COVID-19 on clinical trial activities of our licensees, potential milestone payments may be delayed.
  • Revenues recognized under the units-of-revenue method include the amortization of unearned revenue from the sale of royalty interests to HealthCare Royalty Partners II, L.P (“HCRP”) in 2016. The increase in revenues for the three months ended March 31, 2021, as compared to the same period in 2020, was primarily due to the increase in sales of products underlying the agreements with HCRP.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: AB, Affimed, American, annum, Assembly, assist, attempt, Attorney, BBA, Biden, Biopharma, Bipartisan, blockbuster, budget, build, bulk, Canada, cap, carryback, catastrophic, Certificate, cetrelimab, checking, CMS, comment, consecutive, constitutionality, consulting, deal, delisting, Denovo, deposit, depositary, derecognition, donut, dosed, encourage, EPS, foregoing, fractional, gap, hand, HHS, hinder, hole, ICE, Importantly, impossible, inconsistent, infrastructure, inhibitor, injunction, innate, invasive, involuntary, issuer, junior, jurisdiction, kinase, loosen, mezagitamab, nationwide, newly, Northern, optimize, outage, par, parity, percent, perpetual, pharmacy, post, preliminary, prorated, rank, ranking, reconsider, reexamining, refund, riot, risky, segregated, sequester, singly, speculative, split, spouse, Subtopic, subtracted, suite, summarized, Taxpayer, tie, topoisomerase, Torreya, ulcerative, underpayment, Undistributed, unnecessary, unrestricted, vaccine, Viracta, volume, vosaroxin, waiver
Removed: accelerating, actively, Affordable, AMT, backstopped, Berkeley, bowel, Brazil, Cadila, characterized, clarifying, commenced, Committee, Conceptual, conclude, consist, deduction, description, doubtful, Education, emerging, entrance, exhausted, fill, fluctuate, governance, GP, headcount, historic, improvement, increasing, India, inflammatory, instrument, Interaction, invest, judicial, laboratory, landlord, leased, listing, LP, Maintaining, Mexico, narrative, notifying, opening, Partnership, passage, permitting, precedent, presenting, prospectively, retrospectively, Sarl, serve, shareholder, sharing, slight, staggered, strategic, sublease, subleased, subscription, temporarily, uncollectible, unit, vacated, vulnerability

Patents

APP
Utility
Antibodies That Bind INTERLEUKIN-2 and Uses Thereof
24 Jun 21
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
GRANT
Utility
Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof
15 Jun 21
M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
APP
Utility
Methods for the Treatment of Gout
4 Feb 21
Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.
APP
Utility
Cardiovascular Related Uses of IL-1BETA Antibodies and Binding Fragments Thereof
14 Jan 21
Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies and fragments thereof).
GRANT
Utility
Antibodies that bind interleukin-2 and uses thereof
7 Dec 20
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.